Why EXACT Sciences Corporation Is Rising Today
Shares of EXACT Sciences (NASDAQ: EXAS), a company focused on colon-cancer detection, rose as much as 13% in early morning trading on Wednesday in response to reporting better-than-expected second-quarter results.
Here's a review of the key highlights from the period that have traders feeling giddy today:
The solid quarterly performance allowed management to significantly raise its guidance for the year. Management now expects to complete at least 550,000 Cologuard tests during 2017. That's quite a big jump from the 470,000 tests that management had forecasted just three months ago.
Source: Fool.com
Exact Sciences Aktie
59,16 €
-3,07 %
Die Community bevorzugt Exact Sciences mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein Kursziel von 76 € für Exact Sciences signalisiert eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 59.16 €.
